Increased mdm-2 expression in a p53-independent manner blocks UV-induced cell cycle arrest and apoptosis in human osteosarcoma cells

Tumor Biology

Volumn 24, Issue 3, 2003, Pages 130-139

  Dong, Yan Bin ^a   Yang, Hai Liang ^a   Elliott, Mary Jane ^a   McMasters, Kelly M ^a,b  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Apoptosis; Cell cycle arrest; MDM 2; Osteosarcoma; p53; Transcriptional activity; UV irradiation

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL LINE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; OSTEOSARCOMA CELL; PRIORITY JOURNAL; RADIATION RESPONSE; REPORTER GENE; ULTRAVIOLET RADIATION; WILD TYPE;

EID: 0344826673     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073842     Document Type: Article

References (54)

1. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B: Identification of p53 as a sequence-specific DNA-binding protein. Science 1991;252:1708-1711.
2. Lakin ND, Jackson SP: Regulation of p53 in response to DNA damage. Oncogene 1999;18:7644-7655.
3. Amundson SA, Myers TG, Fornace AJ Jr: Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress. Oncogene 1998;17:3287-3299.
4. Bennett MR: Mechanisms of p53-induced apoptosis. Biochem Pharmacol 1999;58:1089-1095.
5. Gottlieb TM, Oren M: p53 and apoptosis. Semin Cancer Biol 1998;8:359-368.
6. El-Deiry WS: Regulation of p53 downstream genes. Semin Cancer Biol 1998;8:345-357.
7. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutation in the p53 gene occur in diverse human tumor types. Nature 1989;342:705-708.
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutation in human cancers. Science 1991;253:49-53.
9. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992;89:7262-7266.
10. Lane DP, Crawford LV: T antigen is bound to a host protein in SV40-transformed cells. Nature 1979;278:261-263.
11. Werness BA, Levin AJ, Howley PM: Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 1990;248:76-79.
12. Sarnow P, Ho YS, Williams J, Levine AJ: Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 1982;28:387-394.
13. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ, Hill DE, Haber DA: Physical and functional interaction between WT1 and p53 protein. Proc Natl Acad Sci USA 1993;90:5100-5104.
14. O'Connor DJ, Lam EWF, Griffin S, Zhong S, Leighton LC, Burbidge SA, Lu X: Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J 1995;14:6184-6192.
15. Momand J, Zembetti GP, Olson DC, George D, Levine AJ: The mDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
16. Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumour cell line. EMBO J 1991;10: 1565-1569.
17. Finlay CA: The mDM-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993;13: 301-306.
18. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH: mDM-2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-18.
19. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding the p53-associated protein in human sarcomas. Nature 1992;358:80-83.
20. Chen J, Maréchal V, Levine AJ: Mapping of the p53 and mDM-2 interaction domains. Mol Cell Biol 1993;13:4107-4114.
21. Oliner JD, Peitenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncogene MDM-2 conceals the activation domain of tumor suppressor p53. Nature 1993;362:857-860.
22. Haines DS, Landers JE, Engle LJ, George DL: Physical and functional interaction between wild-type p53 and MDM-2 proteins. Mol Cell Biol 1994;14:1171-1178.
23. Zauberman A, Barak Y, Ragimov N, Levy N, Oren M: Sequence-specific DNA binding by p53: Identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J 1993;12:2799-2808.
24. Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by MDM-2. Nature 1997;387:299-303.
25. Haupt Y, Maya R, Kazaz A, Oren M: MDM-2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
26. Chen C-Y, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB: Interactions between p53 and MDM-2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 1994;91:2684-2688.
27. Chen JD, Wu X, Lin JY, Levine AJ: MDM-2 inhibits G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996;16:2445-2452.
28. Chen L, Agrawal S, Zhou W, Zhang R, Chen J: Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 1998;95:195-200.
29. Barak Y, Juven T, Hafner R, Oren M: MDM-2 expression is induced by wildtype p53 activity. EMBO J 1993;12:461-468.
30. Otto A, Deppert W: Upregulation of MDM-2 expression in Meth A tumor cells tolerating wild-type p53. Oncogene 1993;8:2591-2603.
31. Juven T, Barak Y, Zauberman A, George DL, Oren M: Wild-type p53 can mediate sequence-specific transactivation of an internal promoter within the mDM-2 gene. Oncogene 1993;8: 3411-3416.
32. Barak Y, Gottlieb E, Juven T, Oren M: Regulation of MDM-2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 1994;8: 1739-1749.
33. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M: A functional p53-responsive intronic promoter is contained within the human mDM-2 gene. Nucleic Acids Res 1995;23: 2584-2592.
34. Wu X, Bayle JH, Olson D, Oren M: The p53-MDM-2 autoregulatory feedback loop. Gene Dev 1993;7:1126-1132.
35. Piette J, Neel H, Maréchal V: mDM-2: Keeping p53 under control. Oncogene 1997;15:1001-1010.
36. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ: The mDM-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 1993;90:11623-11627.
37. Leach FS, Tokins T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 mutation and mDM-2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-2234.
38. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;256:827-830.
39. Lu X, Burgidge SA, Griffin S, Smith HM: Discordance between accumulated p53 protein level and its transcriptional activity in response to u.v. radiation. Oncogene 1996;13:413-418.
40. Mayo LD, Turchi JJ, Berberich SJ: MDM-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res 1997;57:5013-5016.
41. Momand J, Zambetti GP: Analysis of the proportion of p53 bound to MDM-2 in cells with defined growth characteristics. Oncogene 1996;12:2279-2289.
42. Shieh SY, Ikeda M, Taya Y, Prives C: DNA-damage-induced phosphorylation of p53 alleviates inhibition by MDM-2. Cell 1997;91:325-334.
43. Kussie PH, Gorina S, Maréchal V, Elenbaas B, Moreau J, Levine AJ, et al: Structure of the MDM-2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274:948-953.
44. Lundgren K, de Oca Luna RM, McNeill YB, Emerick EP, Spencer B, Barfield CR, et al: Targeted expression of MDM-2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997;11:714-725.
45. Xiao Z, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM-2. Nature 1995;375: 694-698.
46. Martin K, Trouche D, Hagemeier C, Sorensen TS, Lathangue NB, Kouzarides T: Stimulation of E2F1/DP1 transcriptional activity by MDM-2 oncoprotein. Nature 1995;375:691-694.
47. Mosner J, Deppert W: p53 and MDM-2 are expressed independently during cellular proliferation. Oncogene 1994;9:3321-3328.
48. Alkhalaf M, Ganguli G, Messaddeq N, LeMeur M, Wasylyk B: MDM-2 overexpression generates a skin phenotype in both wild-type and p53 null mice. Oncogene 1999;18:1419-1434.
49. Maréchal V, Elenbaas B, Piette J, Nicolas J, Levine AJ: The ribosomal L5 protein is associated with MDM-2 and MDM-2-p53 complexes. Mol Cell Biol 1994;14:7414-7420.
50. Elenbaas B, Dobbelstein M, Roth J, Shenk T, Levine AJ: The MDM-2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 1996;2:439-451.
51. Fiddler TA, Smith L, Tapscott SJ, Thayer MJ: Amplification of mdm-2 inhibits MyoD-mediated myogenesis. Mol Cell Biol 1996;16: 5048-5057.
52. Dobbelstein M, Wienzek S, Konig C, Roth J: Inactivation of p53-homologue p73 by the MDM-2 oncoprotein. Oncogene 1999;18: 2101-2106.
53. Erhardt P, Tomaselli KJ, Cooper GM: Identification of the MDM-2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J Biol Chem 1997;272:15049-15052.
54. Chen L, Maréchal V, Moreau J, Levine AJ, Chen J: Proteolytic cleavage of MDM-2 onco-protein during apoptosis. J Biol Chem 1997; 272:22966-22973.